Lil­ly's mirik­izum­ab, once a con­tender for pso­ri­a­sis, bol­sters case for UC in­di­ca­tion in main­te­nance tri­al da­ta read­out

Ear­ly last year, Eli Lil­ly an­nounced that in­stead of tak­ing its block­buster con­tender mirik­izum­ab for­ward to the FDA for pso­ri­a­sis, it would be es­sen­tial­ly go­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER